Editas Medicine Makes New Appointments
This article was originally published in Scrip
Genome editing company, Editas Medicine, has appointed Timothy D. Hunt senior vice president of corporate affairs and Haiyan Jiang vice president of preclinical science. Hunt joins Editas from Cubist Pharmaceuticals where he was senior vice president of public affairs, before it was acquired by Merck last year. Jiang started her career as a scientist at Avigen and before joining Editas, she was senior director of cell and gene therapy at Biogen.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.